跳至主要内容
临床试验/JPRN-UMIN000025418
JPRN-UMIN000025418招募中未知

Comparing effect of lipid profile and lipid metabolism by SGLT2 inhibitor Empagliflozin in patient with type 2 diabetes. - Comparing effect of lipid profile and lipid metabolism by SGLT2 inhibitor Empagliflozin in patient with type 2 diabetes.

Department of Endocrinology and Metabolism, Dokkyo Medical University0 个研究点目标入组 30 人开始时间: 2016年12月26日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with Ezetimibe 8)Patient with intolerance of medical reasons by doctor.

研究者

发起方
Department of Endocrinology and Metabolism, Dokkyo Medical University

相似试验